Tiger Medicine push-share incentive drivers are also in doubt

Every reporter Liu Mingtao yesterday (September 18), Tiger Medicine (300347, closing price 57.82 yuan) of an equity incentive plan issued, the company intends to issue the way to the middle management and core personnel to grant 3 million stock options.　　It is worth mentioning that the first line of the right of ownership price of 54.57 yuan, slightly higher than the closing prices before the suspension, it is not difficult to see management confidence. However, some investors in the daily economic news reporter said that the tiger Medicine published in the list of equity incentives for drivers to appear, it is difficult to understand.　　In response, the company responded that it was a special case because of their long working experience. Incentives for middle-class tiger medicine yesterday launched an equity incentive plan to push 3 million stock options, accounting for about 2.81% of the company's total equity, with 2.7 million for the first time, accounting for 90% of the total number of shares granted.　　The equity incentive was awarded to a total of 173 middle managers and core technology (business) personnel who were identified by the Board of Directors as having a direct impact on the company's performance and future development. It is noteworthy that the equity incentive to the first line of the right price of 54.57 yuan, slightly higher than the close of 54.45 yuan before the suspension, such a premium incentive is not difficult to see the company's determination. The incentive program is valid for 4 years, the target can be in the first authorization date 12 months after the proportion of 30%, 30%, 40% of the right to batch. The right condition is: First, take 2012 year operating income as the base, 2013 ~2015 Annual income growth rate is not lower than 26.06%, 60.01% and 104.47% respectively, the second is to 2012 year net profit as the base, 2013 ~2015 annual net profit growth rate is not less than 30%,　　70.3% and 124.8%, and to deduct the net profit and do not deduct the lower number of the net profit as the basis for calculation.　　The driver also had a draft of the equity incentive. Chen Ruibo, the top director of the Medical V Department, has 78,900 stock options, and 173 of them have 2.7 million options and 15,600 per capita in 173 of the subjects being motivated. But some investors told reporters, "Tiger Medicine's equity incentive target is the company's middle managers and core technical staff, but the list is the executive part of the driver, is the driver is also a core technical personnel or middle management personnel?" "The Daily economic news reporter notes that there are 3 drivers in the Equity incentive list, and they have 7,511 options respectively."　　In this respect, tiger medical staff told reporters that they have a long job seniority, is a special case, but the specific standards are not clear. Data show that since this year, many listed companies have launched equity incentive schemes.　　But most of the incentive targets for management or core backbone, such as the Crown Hao Biological, Otter Xun, for the incentive to choose the driver of the situation is less rare. Some private-equity activists told reporters that the aim of the equity incentive is to stabilize the current team, motivate old employees or ordinary employees to createDemonstration effect, benefit team stability.